Pan-cancer landscape of homologous recombination deficiency
Cancers deficient in homologous recombination can benefit from treatment with poly ADP-ribose polymerase (PARP) inhibitors. Here, the authors generated a classifier that can predict homologous recombination deficiency from genomic data and suggest several cancer types that may benefit from PARP inhi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-11-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-19406-4 |